Tiotropium in Patients With Tuberculosis (TB) Destroyed Lung (NCT01365702) | Clinical Trial Compass
UnknownNot Applicable
Tiotropium in Patients With Tuberculosis (TB) Destroyed Lung
South Korea70 participantsStarted 2011-06
Plain-language summary
The aim of this study to evaluate clinical efficacy of tiotropium in patients with airflow obstruction due to Tuberculosis (TB) destroyed lung.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* previous pulmonary tuberculosis history
* never smoker or light smoker (\<10 pack-year)
* destruction of lung parenchyme, lung volume loss,secondary bronchiectasis due to tuberculosis in chest radiographs or chest CT, confirmed by board-certificate radiologist
* airflow obstruction confirmed by pulmonary function test, FEV1/FVC \<70%
Exclusion Criteria:
* patients do not agree with study enrollment
* patients with active tuberculosis or current antituberculous medication
* patients under chemotherapy or other immunosuppressant therapy such as glucocorticoid.
* active infection such as pneumonia, tuberculosis
* patients who are illiterate
* patients with dementia
* pregnant or to be pregnant
* previous lung resection surgery history
What they're measuring
1
St-George respiratory questionnaire(SGRQ)
Timeframe: 6 months after initiation of tiotropium once-daily inhalation